Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

Documenti analoghi

• Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
  di: Chia‐Ming Lin, et al.
  Pubblicazione: (2025)
• Ocular Complications of SGLT ‐2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in T2DM Treatments: A Retrospective Real‐World Cohort Study
  di: Lee‐Yuan Lin, et al.
  Pubblicazione: (2025)
• Front Cover
  di: Chia‐Ming Lin, et al.
  Pubblicazione: (2025)
• SGLT2 Inhibitors and GLP‐1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta‐Analysis
  di: Erin F. Barreto, et al.
  Pubblicazione: (2026)
• Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
  di: Yazan Alhamdan, et al.
  Pubblicazione: (2026)